Archive: UCSF Renal Transplant Service Medical Director Presents Findings to World Transplant Congress

At the World Transplant Congress (WTC) in Boston on July 24, Stephen Tomlanovich, MD, presented the findings of a three-month, prospective, open-label, two-cohort research study in which renal transplant patients were switched from mycophenolate mofetil (MMF) to enteric-coated myfortic, reducing the incidence and severity of gastrointestinal complications. Tomlanovich is medical director of the renal transplant service at the University of California, San Francisco. Links: Switch to Enteric-Coated Myfortic Can Reduce GI Burden in Renal Transplant Patients: Presented at WTC
Doctor's Guide, July 27, 2006